LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Beth Ellyn McClendon: If you want investors, skip LLCs and form a C-Corp
Editor’s note: Beth Ellyn McClendon is a seed-stage investor with board and advisory board experience. She previously worked in design and product management for Google Mapping, Android, YouTube, Cisco and Netscape. The opinions expressed in this commentary are the author’s alone. So, you’re planning a startup, you’ve got a good lawyer and now you’re thinking…
Popular TEDxKC won’t return in 2018; organizers to focus on women, youth events
TEDxKC — one of the largest and most-popular independently-organized TEDx events in the world — won’t be back for 2018. While TEDxYouth@KC and TEDxKCWomen are expected to return in 2018, hitting pause on TEDxKC’s “general ideas” event will allow organizers to reflect on accomplishments, missteps and milestones, said Mike Lundgren, co-founder of TEDxKC. “We asked two…
Fitbit integrating Sickweather illness forecasting into new wearables
Sickweather is stepping into the wearables market. A new partnership with industry leader Fitbit is expected to see the Kansas City-based startup’s illness forecasting technology integrated into Fitbit’s new products. “Smartwatches provide a powerful platform to deliver important health tools that help our users manage conditions more conveniently than ever before,” said James Park, co-founder…
Surveys, rewards dying: Tapyness scores customer feedback with one-tap, 3-second experience
No one takes 15-minute surveys anymore, said Matthew Korte, co-founder of Tapyness, a Lawrence-based customer experience platform that provides real-time feedback via kiosks in client businesses. A typical Tapyness interaction takes three seconds, he said. “We’re down to the millisecond, and we’re aggregating hundreds of tablets simultaneously within one brand to go: ‘Here’s the health…